Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

TP53 in bone and soft tissue sarcomas.

Thoenen E, Curl A, Iwakuma T.

Pharmacol Ther. 2019 Jul 2. pii: S0163-7258(19)30119-6. doi: 10.1016/j.pharmthera.2019.06.010. [Epub ahead of print] Review.

PMID:
31276706
2.

Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradation.

Han Y, Wu P, Wang Z, Zhang Z, Sun S, Liu J, Gong S, Gao P, Iwakuma T, Molina-Vila MA, Chen BP, Zhang Y, Ji T, Mo Q, Chen P, Hu J, Wang S, Zhou J, Lu H, Gao Q.

EBioMedicine. 2019 Feb;40:92-105. doi: 10.1016/j.ebiom.2019.01.002. Epub 2019 Jan 20.

3.

Regulators of Oncogenic Mutant TP53 Gain of Function.

Yamamoto S, Iwakuma T.

Cancers (Basel). 2018 Dec 20;11(1). pii: E4. doi: 10.3390/cancers11010004. Review.

4.

MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma.

Ranjan A, Iyer SV, Ward C, Link T, Diaz FJ, Dhar A, Tawfik OW, Weinman SA, Azuma Y, Izumi T, Iwakuma T.

Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20.

5.

Emerging Non-Canonical Functions and Regulation of p53.

Ranjan A, Iwakuma T.

Int J Mol Sci. 2018 Mar 28;19(4). pii: E1015. doi: 10.3390/ijms19041015.

6.

Comparative oncology approach to drug repurposing in osteosarcoma.

Parrales A, McDonald P, Ottomeyer M, Roy A, Shoenen FJ, Broward M, Bruns T, Thamm DH, Weir SJ, Neville KA, Iwakuma T, Fulbright JM.

PLoS One. 2018 Mar 26;13(3):e0194224. doi: 10.1371/journal.pone.0194224. eCollection 2018.

7.

The interplay between mutant p53 and the mevalonate pathway.

Parrales A, Thoenen E, Iwakuma T.

Cell Death Differ. 2018 Mar;25(3):460-470. doi: 10.1038/s41418-017-0026-y. Epub 2017 Dec 13. Review.

8.

Regulation of cytotoxic T-cell responses by p53 in cancer.

Braun MW, Iwakuma T.

Transl Cancer Res. 2016 Dec;5(6):692-697. doi: 10.21037/tcr.2016.11.76.

9.

Nischarin inhibition alters energy metabolism by activating AMP-activated protein kinase.

Dong S, Baranwal S, Garcia A, Serrano-Gomez SJ, Eastlack S, Iwakuma T, Mercante D, Mauvais-Jarvis F, Alahari SK.

J Biol Chem. 2017 Oct 13;292(41):16833-16846. doi: 10.1074/jbc.M117.784256. Epub 2017 Aug 24.

10.

Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma.

Kundu AK, Iyer SV, Chandra S, Adhikari AS, Iwakuma T, Mandal TK.

PLoS One. 2017 Jun 21;12(6):e0179168. doi: 10.1371/journal.pone.0179168. eCollection 2017.

11.

Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB.

Parrales A, Ranjan A, Iwakuma T.

Stem Cell Investig. 2017 Jun 3;4:49. doi: 10.21037/sci.2017.05.07. eCollection 2017. No abstract available.

12.

RIPK1-TRAF2 interplay on the TNF/NF-κB signaling, cell death, and cancer development in the liver.

Yamamoto S, Iwakuma T.

Transl Cancer Res. 2017 May;6(Suppl 3):94-109. doi: 10.21037/tcr.2017.04.01. No abstract available.

13.

Suppressive roles of A3AR and TMIGD3 i1 in osteosarcoma malignancy.

Ranjan A, Iyer SV, Iwakuma T.

Cell Cycle. 2017 May 19;16(10):903-904. doi: 10.1080/15384101.2017.1308153. Epub 2017 Mar 29. No abstract available.

14.

Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer.

Sasaki K, Kurahara H, Young ED, Natsugoe S, Ijichi A, Iwakuma T, Welch DR.

Clin Exp Metastasis. 2017 Apr;34(3-4):229-239. doi: 10.1007/s10585-017-9840-3. Epub 2017 Mar 13.

15.

Roles of p53 in extrinsic factor-induced liver carcinogenesis.

Link T, Iwakuma T.

Hepatoma Res. 2017;3:95-104. doi: 10.20517/2394-5079.2017.07. Epub 2017 Jun 6.

16.

p53 as a Regulator of Lipid Metabolism in Cancer.

Parrales A, Iwakuma T.

Int J Mol Sci. 2016 Dec 10;17(12). pii: E2074. Review.

17.

Non-Canonical Cell Death Induced by p53.

Ranjan A, Iwakuma T.

Int J Mol Sci. 2016 Dec 9;17(12). pii: E2068. Review.

18.

Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression.

Iyer SV, Ranjan A, Elias HK, Parrales A, Sasaki H, Roy BC, Umar S, Tawfik OW, Iwakuma T.

Nat Commun. 2016 Nov 25;7:13561. doi: 10.1038/ncomms13561.

19.

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.

Parrales A, Ranjan A, Iyer SV, Padhye S, Weir SJ, Roy A, Iwakuma T.

Nat Cell Biol. 2016 Nov;18(11):1233-1243. doi: 10.1038/ncb3427. Epub 2016 Oct 24.

20.

Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen.

Kurahara H, Bohl C, Natsugoe S, Nishizono Y, Harihar S, Sharma R, Iwakuma T, Welch DR.

Int J Cancer. 2016 Aug 1;139(3):628-38. doi: 10.1002/ijc.30110.

Supplemental Content

Loading ...
Support Center